ASP Isotopes, Inc. (ASPI)
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-09-04
$4.20+7.69%
Close 2026-09-04 · 1-day change
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-09-04
Intact: The reason to own it still holds.
ASPI plans to start selling Silicon-28 in Q3 2026. It aims for $10 million revenue from radiopharmacies in 2026, doubling 2025. The company expects to produce LNG and helium commercially in Q3 2026. These steps could help ASPI grow and improve.
ASPI is losing money and faces many lawsuits. Earnings estimates are getting worse. The recent big stock drop shows investors doubt the turnaround. The company might fail to meet its sales and production goals.
The market has sold off ASPI shares sharply, reflecting doubts about its turnaround. There is no clear consensus revenue growth priced in. Our view is cautious given the losses and legal risks.
Breaks if: Commercial production does not start by end of Q3 2026
Breaks if: Radiopharmacy revenue falls below $5 million in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth scenario. The company is currently loss-making and has volatile management, which adds to the uncertainty of its future performance.
The market seems to be pricing in a cautious outlook due to ASPI's recent earnings miss and ongoing litigation. Current expectations may reflect a belief that the company will struggle to meet its growth targets in the near term.
Management's execution on key priorities, such as ramping up helium and LNG production, is mixed but shows some promise. However, the company has a high probability of missing earnings expectations, which could further impact its performance.
The future of ASPI hinges on its ability to meet production targets and manage risks effectively. Additionally, external factors like inflation trends and performance of sector leaders will play a crucial role in shaping its trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company advanced its plans for commercial shipments of enriched isotopes in 2026. This development reinforces the thesis around ASPI's growth potential. There are no new threats identified that could weaken this outlook.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Initial shipments do not begin by end of Q3 2026
Over the next 1 to 3 years, ASPI's outlook remains uncertain, with significant risks and mixed management performance. Not investment advice.